Compare ITT & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ITT | NBIX |
|---|---|---|
| Founded | 1920 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 15.5B |
| IPO Year | 1994 | 1996 |
| Metric | ITT | NBIX |
|---|---|---|
| Price | $202.62 | $154.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 22 |
| Target Price | ★ $216.45 | $180.91 |
| AVG Volume (30 Days) | 822.3K | ★ 1.4M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.73% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 1.84 | ★ 3.30 |
| Revenue | ★ $3,938,500,000.00 | $161,626,000.00 |
| Revenue This Year | $32.87 | $24.73 |
| Revenue Next Year | $9.78 | $13.14 |
| P/E Ratio | $113.02 | ★ $47.25 |
| Revenue Growth | 8.48 | ★ 977.51 |
| 52 Week Low | $166.96 | $122.14 |
| 52 Week High | $230.32 | $186.12 |
| Indicator | ITT | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 50.03 | 42.55 |
| Support Level | $179.09 | $152.67 |
| Resistance Level | $208.84 | $161.29 |
| Average True Range (ATR) | 5.28 | 3.72 |
| MACD | -1.41 | 0.28 |
| Stochastic Oscillator | 18.68 | 41.35 |
ITT began its journey as International Telephone & Telegraph in 1920. Through decades of acquisitions in the mid-1900s, ITT went from manufacturing telephone switching equipment to operating hotels, car rentals, insurance agencies, and bread bakeries. In 1995, the firm split into three separate entities, one of which is the ITT in current operation. After a few more spinoffs in 2011, today ITT Inc. sells automotive, industrial, and aerospace products such as brake pads, seals, pumps, valves, connectors, and regulators. It has operations around the globe with notable exposures to North America, Europe, and Asia.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.